Biotechnology
SK Biopharmaceuticals Seals 1st Actinium-225-Based Collaborative Research Agreement with Korea Institute of Radiological and Medical Sciences as Steps Toward Becoming Global Radiopharmaceutical Therapy Player
* SK Biopharmaceuticals, Korea Institute of Radiological and Medical Sciences collaborate on discovering and developing radiopharmaceutical drug candidates using analpha-particle emitting radioisotope, actinium-225, for potential cancer treatments * The two sides aim to submit an Investigatio...
2024-11-19 08:00
2367
C Ray Therapeutics Completes Over $100 Million Series A+ Financing, Jointly Led by SCGC and TaiLong Capital
CHENGDU, China, Nov. 18, 2024 /PRNewswire/ -- In November 2024, C Ray Therapeutics (Chengdu) Co., Ltd. (hereinafter referred to as "C Ray"), an innovative enterprise in the field of radiopharmaceuticals, announced the completion of its Series A+ financing round exceeding$100 million. This round ...
2024-11-18 22:00
3039
Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets
* Biosion receives over $40 million cash payment as upfront license fee and reimbursement for certain development costs & drug product materials, and 19.9% shares of common stock of Aclaris Therapeutics; additional regulatory and sales milestone payments exceed$900M with tiered single digit sal...
2024-11-18 21:50
2189
FDA Grants Breakthrough Therapy Designation to Huahui Health's Libevitug (HH-003) for treatment of chronic Hepatitis D virus infection
BEIJING, Nov. 18, 2024 /PRNewswire/ -- Huahui Health, a clinical-stage biotechnology company focused on discovering and developing novel therapies in the areas of viral hepatitis, hepatology, and oncology, today announced that its investigational hepatitis D and B drug candidate, Libevitug (HH-00...
2024-11-18 18:40
1704
SoniVie Ltd., Appoints Veteran Medtech Executive Raymond W. Cohen as Chairman of its Board of Directors
TEL AVIV, Israel, Nov. 14, 2024 /PRNewswire/ -- SoniVie Ltd.
2024-11-18 08:00
1952
Neurophet Appoints CTO Donghyeon Kim as Co-CEO, Joining Jake Junkil Been in Dual Leadership to Drive Global Growth
- Donghyeon Kim, Co-Founder and CTO of Neurophet, to Take On Dual Role as CEO, Heading Technology and Company Leadership - Aims to Strategically Expand Business and Management Functions for Establishing a Strong Presence in Global Markets SEOUL, South Korea, Nov. 15, 2024 /PRNewswire/ -- Neuroph...
2024-11-15 22:00
2667
Acepodia Announces FDA Clearance of Investigational New Drug Application for ACE1831 in IgG4-Related Disease
* IND clearance paves the way for Acepodia to enter the clinic for the first time with its autoimmune program * ACE1831 is an allogeneic gamma delta T cell therapy candidate targeting CD20-expressing cells currently being investigated in non-Hodgkin's lymphoma (NHL) * The planned clinical ...
2024-11-15 20:00
2093
Angel Yeast Turns Automation into Opportunity, Ensuring No Job Losses
YICHANG, China, Nov. 15, 2024 /PRNewswire/ -- Angel Yeast has taken a significant step towards modernization and sustainability by automating its packaging line while ensuring no layoffs for its employees. In 2024, with the completion of the intelligent transformation of its packaging workshop, t...
2024-11-15 20:00
2246
Harbour BioMed Appoints Dr. Raymond Zheng as Chief Business Officer
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Nov. 14, 2024 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunol...
2024-11-15 09:55
2143
I-Mab Reports Third Quarter 2024 Results
* Givastomig data presented at ESMO 2024 and SITC 2024 highlights encouraging monotherapy data * On track to dose first patient in randomized Phase 2 study of uliledlimab in first-line mNSCLC in 1H 2025 * Appointed Dr. Sean Fu as permanent CEO effective November 1, 2024 * Estimated cash ru...
2024-11-14 20:00
1953
Join the GenScript Biotech Global Forum in London to Navigate the Future of Cell and Gene Therapies.
PISCATAWAY, N.J., Nov. 13, 2024 /PRNewswire/ -- The global cell and gene therapy (CGT) industry is poised for remarkable growth, driven by significant advances in life sciences and robust investments from capital markets. To strengthen this vital sector, GenScript is bringing together leading sc...
2024-11-13 23:51
1762
Insilico Medicine Announces Positive Topline Results of ISM001-055 for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) Developed Using Generative AI
Highlights: * ISM001-055 was safe and well-tolerated with a favorable PK profile in IPF patients * Patients who received ISM001-055 showed dose-dependent improvement in the efficacy endpoint, as measured by change in forced vital capacity (FVC) at 12 weeks CAMBRIDGE, Mass., Nov. 12, 2024 /...
2024-11-12 22:00
2206
Chime Biologics and Waterstone Announce a Strategic Partnership to Empower Antibody-Drug Conjugate (ADC) Development and Manufacturing
* Chime Biologics and Waterstone Pharmaceuticals announce a strategic partnership to provide integrated services for the global Antibody-Drug Conjugate (ADC) industry. * Chime Biologics will leverage its CMC expertise in biologics to manage Antibody Intermediate, ADC Drug Substance and Drug P...
2024-11-12 21:15
2289
Tsingke Successfully Showcases Innovations at BIO-Europe 2024
BEIJING, Nov. 12, 2024 /PRNewswire/ -- Tsingke
2024-11-12 17:07
1683
WuXi AppTec Ranked #1 in Global Life Sciences Tools & Services Industry in 2024 S&P Global Corporate Sustainability Assessment
SHANGHAI, Nov. 11, 2024 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, has been ranked #1 in the global Life Sciences Tools & Services sector in the 2024 S&P Glo...
2024-11-12 08:00
2229
Neurizon Therapeutics Receives Positive Opinion on Orphan Medicinal Product Designation for NUZ-001 in Europe
Highlights: * Notice of positive opinion received from the European Medicines Agency for Orphan Medicinal Product Designation for NUZ-001 in Amyotrophic Lateral Sclerosis * Orphan Designation offers 10 years of market exclusivity in Europe upon product approval, along with additional regulat...
2024-11-11 20:30
2096
Alteogen enters into an Exclusive License Agreement to Develop and Commercialize Subcutaneous ENHERTU® Enabled by Alteogen's Hybrozyme™ Technology
DAEJEON, South Korea, Nov. 10, 2024 /PRNewswire/ -- Alteogen Inc. (KOSDAQ:196170) announced today that the company has entered into an exclusive license agreement with Daiichi Sankyo (TSE: 4568). Under the terms of the agreement, Daiichi Sankyo will acquire world-wide rights to use ALT-B4, Alteo...
2024-11-11 08:07
2457
Mabwell Reveals Encouraging Pre-clinical Data of 7MW4811 at the 15th World ADC Conference
SHANGHAI, Nov. 8, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, showcased the "Preclinical Development of 7MW4811, an Mtoxin™ (MF6)-based Antibody-drug Conjugate for the Treatment of Solid Tumors" as a poster presentation at the 15 t...
2024-11-08 22:00
3154
Samsung Biologics earns ISO certifications in recognition of business excellence
* The company adds new ISO certification for compliance management and certified to updated standards for information and cloud security * Certifications recognize Samsung Biologics' commitment to operational excellence and demonstrates the company's reliability and integrity as a trusted CDM...
2024-11-08 20:00
2190
Dizal Submits New Drug Application to the U.S. FDA for Sunvozertinib in Treating Relapsed or Refractory Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
The submission is supported by data from the pivotal WU-KONG1 Part B study, which featured in an oral session at the 2024 ASCO Annual Meeting Sunvozertinib is the world's first and only oral drug approved for NSCLC patients with EGFR exon20ins SHANGHAI, Nov. 8, 2024 /PRNewswire/ -- Dizal (SSE:68...
2024-11-08 18:01
2098
Week's Top Stories
Most Reposted
Agoda Launches Agoda Impact Lab at ASEAN Tourism Forum
[Picked up by 318 media titles]
2026-01-29 15:06
Agoda Launches Open-Source API Agent to Simplify MCP Server Integrations
[Picked up by 309 media titles]
2026-01-27 13:00
Nokia Strengthens Edge AI Capabilities Through Strategic Collaboration with Blaize on Hybrid Inference Solutions Across Asia Pacific Regions
[Picked up by 294 media titles]
2026-01-27 18:00
Multi-Award Winning Phuket Marriott Resort & Spa, Merlin Beach: Voted Top 3 Best Family Resort
[Picked up by 283 media titles]
2026-01-30 08:00
True 1000Hz Powerhouse: PHILIPS EVNIA Unleashes the World's First 1000Hz Dual-Mode Gaming Monitor 27M2N5500XD
[Picked up by 282 media titles]
2026-01-29 18:03
